MedPath

The efficacy of prophylactic Sulbactam/Ampicillin in the treatment of perineal wound infection after abdominoperineal resection. Multicenter randomized controlled study

Not Applicable
Conditions
Rectal cancer, Anal canal cancer
Registration Number
JPRN-UMIN000042658
Lead Sponsor
Tokyo Medical and Dental University Department of Gastrointestinal Surgery
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
80
Inclusion Criteria

Not provided

Exclusion Criteria

Patients who meet any of the following conditions are not eligible (1) Patients with previous hypersensitivity to SBT/ABPC or CMZ (2) Emergency surgery (3) Patients with poorly controlled diabetes (HbA1c over 8.0), chronic renal failure requiring dialysis, and patients requiring immunosuppressive drugs (4) Patients with a systemic active infection or fever (>38 degrees Celsius) and suspected infection (5) Patients who are either pregnant, likely to be pregnant, within 28 days after delivery, or breastfeeding (6) Serious organ failure (7) As a result of preoperative explanations, cases of disagreement (8) Any other patient whom the principal investigator or the researcher determines to be unsuitable for the safe conduct of the study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Incidence of perineal wound infection within 30 days after surgery
Secondary Outcome Measures
NameTimeMethod
1 Incidence of all SSI(surgical site infection) 2 Percentage of all complications, excluding SSI, within 30 days of surgery. 3 Methicillin-resistant Staphylococcus Aureus (MRSA) detection rate 4 Post-operative hospital stay
© Copyright 2025. All Rights Reserved by MedPath